Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$1.08M$1.08M−14.3% vs Q1 2016 Net Income-$1.50M-$1.50MN/M vs Q1 2016 EPS Diluted-$0.03-$0.03N/M vs Q1 2016 Gross Profit$48,000−42.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$1,353,000N/M Free Cash Flowderived-$1,500,000N/M Margins · derivedGross margin4.4%−2.1 pt vs Q1 2016
Operating margin-145.7%−59.2 pt vs Q1 2016
Net margin-138.6%−57.8 pt vs Q1 2016
ended Sep 30, 2016 · filed Nov 9, 2016 · 40 d after period end